Skip to main content

Parkinson’s Disease

  • Reference work entry
  • First Online:
Neuroscience in the 21st Century
  • 128 Accesses

Abstract

Parkinson’s disease (PD) is named after the English physician James Parkinson who published the first detailed description of the disorder in the modern Western world. In 1817, Parkinson wrote his “Essay on the Shaking Palsy,” a short monograph which described the features of this disorder. Remarkably, of the six patients he described in his monograph, Parkinson treated only one of these individuals; the remaining five cases were individuals he had simply observed on the streets of his home town of London. Nevertheless, his keen eye noted many of the symptoms which are still considered to be the cardinal characteristics of the disorder he called the “shaking palsy.” In honor of this description, the disease was later named after Parkinson, a term first used by the famous French physician Charcot in the 1880s. Today, PD is the second most common neurodegenerative disease with an estimated five million cases worldwide, although with the aging of the world’s population, the number of individuals with PD in the world is estimated to double by 2030. Thus, this disorder remains as much as a challenge in the twenty-first century as it was when James Parkinson first wrote about it.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 549.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Double KL, Reyes S, Werry EL, Halliday GM (2010) Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol 92:316–329

    Article  CAS  Google Scholar 

  • Foley PB (2003) Beans, roots and leaves. A history of the chemical therapy of Parkinsonism. Tectum, Marburg

    Google Scholar 

  • Halliday GM, Barker RA, Rowe DB (eds) (2011) Non-dopamine lesions in Parkinson’s disease. Oxford University Press, New York

    Google Scholar 

  • Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10:377–393

    Article  CAS  Google Scholar 

  • Olanow CW et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361:1268–1278

    Article  CAS  Google Scholar 

  • Rascol O, Lozano A, Stern M, Poewe W (2011) Milestones in Parkinson’s disease therapeutics. Mov Disord 26:1072–1082

    Article  Google Scholar 

  • Wakeman DR, Dodiya HB, Kordower JH (2011) Cell transplantation and gene therapy in Parkinson’s disease. Mt Sinai J Med 78:126–158

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kay Double .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Science+Business Media, LLC, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Double, K., Finberg, J. (2022). Parkinson’s Disease. In: Pfaff, D.W., Volkow, N.D., Rubenstein, J.L. (eds) Neuroscience in the 21st Century. Springer, Cham. https://doi.org/10.1007/978-3-030-88832-9_112

Download citation

Publish with us

Policies and ethics